Biomea Fusion to Present Late Breaking Data from Ongoing Pha

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

California , United States , Florida , San Diego , Fort Myers , San Diego Convention Center , American , Chunyi Zhao , Rohit Kulkarni , Johnson , Josee Rodriguez , Biomea Fusion Inc , Division Of Endocrinology , Hilton Bayfront Hotel , Healthcare Center Fort Myers , American Diabetes Association , Investor Relations Corporate Development , Professor Of Medicine At Harvard Medical School , University Of California , Twitter , Exchange Commission , Principal Investigator At Velocity Clinical Research , Facebook , Securities Exchange , San Diego School Of Medicine , Linkedin , Faculty Member Of The Joslin Diabetes Center , Scientific Sessions , Biomea Fusion , Diabetes Association , Covalent Menin Inhibitor , Presentation Number , Principal Investigator , Velocity Clinical Research , Clinical Assistant Professor , San Diego School , Medical Affairs , Diabetes Care , Scientific Advisory , Harvard Medical School , Faculty Member , Joslin Diabetes Center , Scientific Advisory Board , Medical Director , Southwest General Healthcare Center , Securities Act , Securities Exchange Act , Exchange Act , Investor Relations ,